The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
J. D. Hainsworth
No relevant relationships to disclose
E. Arrowsmith
No relevant relationships to disclose
M. McCleod
No relevant relationships to disclose
L. Fayad
Research Funding - Lilly
O. Hamid
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
L. Davis
Research Funding - i3 Statprobe
B. K. Lin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly